This book presents a comprehensive update of the latest findings in oncogenetics. It also investigates the relevance of preclinical models with respect to clinical cancer prevention (primary and secondary) for major cancer types such as breast, skin, lung, prostate and colon cancer.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Brook Bookstore On Demand, Napoli, NA, Italien
Zustand: new. Questo è un articolo print on demand. Bestandsnummer des Verkäufers ca27d298731a1f049e1e47bf20cde3e2
Anzahl: Mehr als 20 verfügbar
Anbieter: Basi6 International, Irving, TX, USA
Zustand: Brand New. New. Delivery takes 25-30 days. Excellent Customer Service. Bestandsnummer des Verkäufers POD-192823
Anzahl: Mehr als 20 verfügbar
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Hans-Jorg Senn H.-J. Senn (~) Center for Tumor Detection and Prevention, Rorschacherstr. 150, CH-9006 St. Gallen, Switzerland Clinical oncology has centered mainly on developing new strategies and a multitude of new drugs for fighting relapsing and progressive cancer during the last two decades. Furthermore, it has done this with respectable success in quite a number of neoplastic diseases such as acute leukemias and sarcomas in pediatric patients and certain types of aggressive lymphomas, as well as se lected solid tumors such as testicular cancer and choriocarcinoma in adult age. Curatively intended adjuvant chemo-and endocrine-therapies of several 'main killers' among prevalent cancer types, especially breast and colon can cer, have also become successful and health-politically meaningful therapeutic targets [1, 2]. However, the net gain in 'cure' of these (mostly pharmacologic) therapeu tic approaches has to be realistically judged as having a moderate impact on the cancer problem as a whole, and the mortality rate of the most frequent tu mor types, which are prevalent in adult life, has with very few exceptions not been substantially decreased over the past two to three decades. Increasingly, health politicians, epidemiologists, and medical journal editors are asking for alternative strategies of lowering cancer incidence and increasing survival, ventilating new and hitherto mostly neglected areas of research such as pri mary and secondary cancer prevention. 280 pp. Englisch. Bestandsnummer des Verkäufers 9783642628924
Anzahl: 2 verfügbar
Anbieter: Books Puddle, New York, NY, USA
Zustand: New. pp. 280. Bestandsnummer des Verkäufers 2658597265
Anzahl: 4 verfügbar
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Zustand: New. Print on Demand pp. 280. Bestandsnummer des Verkäufers 50962510
Anzahl: 4 verfügbar
Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New. PRINT ON DEMAND pp. 280. Bestandsnummer des Verkäufers 1858597275
Anzahl: 4 verfügbar
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
Paperback. Zustand: Brand New. reprint edition. 278 pages. 9.25x6.10x0.70 inches. In Stock. Bestandsnummer des Verkäufers x-3642628923
Anzahl: 2 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Hans-Jorg Senn H.-J. Senn (~) Center for Tumor Detection and Prevention, Rorschacherstr. 150, CH-9006 St. Gallen, Switzerland Clinical oncology has centered mainly on developing new strategies and a multitude of new drugs for fighting relapsing and progress. Bestandsnummer des Verkäufers 5065248
Anzahl: Mehr als 20 verfügbar
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book presents a comprehensive update of the latest findings in oncogenetics. It also investigates the relevance of preclinical models with respect to clinical cancer prevention (primary and secondary) for major cancer types such as breast, skin, lung, prostate and colon cancer.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 280 pp. Englisch. Bestandsnummer des Verkäufers 9783642628924
Anzahl: 1 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Hans-Jorg Senn H.-J. Senn (~) Center for Tumor Detection and Prevention, Rorschacherstr. 150, CH-9006 St. Gallen, Switzerland Clinical oncology has centered mainly on developing new strategies and a multitude of new drugs for fighting relapsing and progressive cancer during the last two decades. Furthermore, it has done this with respectable success in quite a number of neoplastic diseases such as acute leukemias and sarcomas in pediatric patients and certain types of aggressive lymphomas, as well as se lected solid tumors such as testicular cancer and choriocarcinoma in adult age. Curatively intended adjuvant chemo-and endocrine-therapies of several 'main killers' among prevalent cancer types, especially breast and colon can cer, have also become successful and health-politically meaningful therapeutic targets [1, 2]. However, the net gain in 'cure' of these (mostly pharmacologic) therapeu tic approaches has to be realistically judged as having a moderate impact on the cancer problem as a whole, and the mortality rate of the most frequent tu mor types, which are prevalent in adult life, has with very few exceptions not been substantially decreased over the past two to three decades. Increasingly, health politicians, epidemiologists, and medical journal editors are asking for alternative strategies of lowering cancer incidence and increasing survival, ventilating new and hitherto mostly neglected areas of research such as pri mary and secondary cancer prevention. Bestandsnummer des Verkäufers 9783642628924
Anzahl: 1 verfügbar